HK1223944A1 - 強化 細胞抗腫瘤效應物運作的方法及複合物 - Google Patents

強化 細胞抗腫瘤效應物運作的方法及複合物

Info

Publication number
HK1223944A1
HK1223944A1 HK16111852.6A HK16111852A HK1223944A1 HK 1223944 A1 HK1223944 A1 HK 1223944A1 HK 16111852 A HK16111852 A HK 16111852A HK 1223944 A1 HK1223944 A1 HK 1223944A1
Authority
HK
Hong Kong
Prior art keywords
compositions
cells
enhanced anti
tumor effector
effector functioning
Prior art date
Application number
HK16111852.6A
Other languages
English (en)
Inventor
Michael Jensen
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Publication of HK1223944A1 publication Critical patent/HK1223944A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/46444—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16111852.6A 2008-08-26 2016-10-14 強化 細胞抗腫瘤效應物運作的方法及複合物 HK1223944A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9191508P 2008-08-26 2008-08-26

Publications (1)

Publication Number Publication Date
HK1223944A1 true HK1223944A1 (zh) 2017-08-11

Family

ID=41721878

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111852.6A HK1223944A1 (zh) 2008-08-26 2016-10-14 強化 細胞抗腫瘤效應物運作的方法及複合物

Country Status (13)

Country Link
US (1) US8822647B2 (zh)
EP (3) EP3006459B1 (zh)
JP (2) JP2012501180A (zh)
CA (2) CA2735456C (zh)
DK (1) DK3006459T3 (zh)
ES (3) ES2961498T3 (zh)
HK (1) HK1223944A1 (zh)
HR (1) HRP20211788T1 (zh)
HU (1) HUE058891T2 (zh)
PL (1) PL3006459T3 (zh)
PT (1) PT3006459T (zh)
SI (1) SI3006459T1 (zh)
WO (1) WO2010025177A1 (zh)

Families Citing this family (299)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090257994A1 (en) * 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US11278594B2 (en) 2001-04-30 2022-03-22 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
ES2620259T3 (es) 2010-04-14 2017-06-28 Roger Williams Medical Center Métodos y composiciones para tratar VIH
NZ609967A (en) * 2010-10-27 2015-04-24 Baylor College Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
DK3214091T3 (en) 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
WO2012082841A2 (en) * 2010-12-14 2012-06-21 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
WO2012082946A2 (en) * 2010-12-14 2012-06-21 The Regents Of The University Of California Creation of super-stable coie1 plasmids by duplication of sl 1-4 sequence and point mutations.
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
RU2688185C2 (ru) 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
PT2694549T (pt) * 2011-04-08 2018-11-22 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização do mesmo para o tratamento de cancro
GB201108236D0 (en) * 2011-05-17 2011-06-29 Ucl Business Plc Method
ES2723181T3 (es) * 2011-07-29 2019-08-22 Univ Pennsylvania Receptores de conmutación coestimulante
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US10421960B2 (en) 2011-09-16 2019-09-24 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
EP3326467B1 (en) * 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
EP2773651B1 (en) * 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US9783591B2 (en) 2012-02-22 2017-10-10 The Trustees Of The University Of Pennsylvania Use of the CD2 signaling domain in second-generation chimeric antigen receptors
MX2014010181A (es) 2012-02-22 2015-03-20 Univ Pennsylvania Uso de cars a base de icos para incrementar la actividad antitumor y persistencia a car.
EP2817318A4 (en) 2012-02-22 2016-04-27 Univ Pennsylvania COMPOSITIONS AND METHOD FOR GENERATING A PERSISTENT POPULATION OF T CELLS FOR CANCER TREATMENT
WO2013126720A2 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
CN110331154A (zh) 2012-04-11 2019-10-15 美国卫生和人力服务部 靶向b-细胞成熟抗原的嵌合抗原受体
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
EA201492222A1 (ru) 2012-05-25 2015-05-29 Селлектис Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
KR20210149195A (ko) * 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
US10780118B2 (en) * 2012-08-20 2020-09-22 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9394368B2 (en) * 2013-02-20 2016-07-19 Novartis Ag Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
EP2958942B1 (en) 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
WO2014138315A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Heparanase expression in human t lymphocytes
CA2905352A1 (en) * 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
ES2837628T3 (es) 2013-03-15 2021-07-01 Celgene Corp Linfocitos T modificados
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CN104140974B (zh) 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
RS63798B1 (sr) * 2013-05-13 2022-12-30 Cellectis Cd19 specifični himerni antigenski receptor i njegove primene
RU2555533C9 (ru) * 2013-05-23 2016-03-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Рекомбинантная плазмидная днк, кодирующая химерное антитело против фактора некроза опухоли-альфа человека, линия эукариотических клеток-продуцент химерного антитела и способ получения химерного антитела
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
CN105899232A (zh) * 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
JP2017504601A (ja) * 2013-12-20 2017-02-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
MY178233A (en) 2013-12-20 2020-10-07 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
CA2937750A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
PE20161211A1 (es) 2014-03-21 2016-11-27 Abbvie Inc Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
IL307423A (en) 2014-04-07 2023-12-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
RU2751920C2 (ru) 2014-04-10 2021-07-20 Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) Экспрессия трансгенов, регулируемая лекарственным средством
AU2015249655B2 (en) * 2014-04-23 2021-01-07 Board Of Regents, The University Of Texas System Chimeric antigen receptors (CAR) for use in therapy and methods for making the same
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
JP6663359B2 (ja) 2014-06-06 2020-03-11 ブルーバード バイオ， インコーポレイテッド 改善されたｔ細胞組成物
US10568947B2 (en) 2014-07-21 2020-02-25 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
RU2747457C2 (ru) 2014-07-24 2021-05-05 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
CN112410363A (zh) 2014-08-19 2021-02-26 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
AU2015308818B2 (en) * 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
CA2959168A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
SG10201902168PA (en) * 2014-09-09 2019-04-29 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015317351B2 (en) * 2014-09-19 2020-07-02 City Of Hope Costimulatory chimeric antigen receptor T cells targeting IL3Ra2
RU2743657C2 (ru) 2014-10-08 2021-02-20 Новартис Аг Биомаркеры, прогнозирующие способность к терапевтическому ответу на терапию химерным рецептором антигена, и их применение
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
IL293714A (en) 2014-10-20 2022-08-01 Juno Therapeutics Inc Methods and preparations for dosing in stress cell therapy
US9650428B2 (en) * 2014-12-02 2017-05-16 Roger Williams Hospital Methods and compositions for treating cancer
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
NZ770737A (en) 2014-12-12 2024-07-05 2Seventy Bio Inc Bcma chimeric antigen receptors
CA3008162A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
JP6768664B2 (ja) 2014-12-24 2020-10-14 アーディジェン， エルエルシー 分子の細胞内送達のためのペプチドおよびナノ粒子
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
MA41433A (fr) * 2015-01-26 2017-12-05 Baylor College Medicine Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
DK3250606T3 (da) 2015-01-26 2021-01-04 Cellectis ANTI-CLL1-specifikke enkeltkædede kimære antigenreceptorer (SCCARS) til cancerimmunterapi
US20180170992A1 (en) * 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
EP3250693B2 (en) 2015-01-30 2023-12-20 The Regents of The University of California Protein delivery in primary hematopoietic cells
KR101755431B1 (ko) * 2015-02-02 2017-07-12 단국대학교 산학협력단 키메릭 항원 수용체(Chimeric antigen receptor) 전달용 CTLA-4 타겟팅 트랜스-스플라이싱 라이보자임 및 이의 용도
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US20160228547A1 (en) * 2015-02-06 2016-08-11 Batu Biologics, Inc. Chimeric antigen receptor targeting of tumor endothelium
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
EP3280437A4 (en) 2015-04-06 2018-09-12 Jianhua Yu Egfr-directed car therapy for glioblastoma
SG11201708191XA (en) 2015-04-08 2017-11-29 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
US10752670B2 (en) * 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
KR20180058659A (ko) 2015-05-20 2018-06-01 노파르티스 아게 에베롤리무스와 닥톨리십의 약제학적 병용물
WO2016196384A1 (en) 2015-05-29 2016-12-08 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
US10711064B2 (en) 2015-06-04 2020-07-14 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Adapted cells and treatment methods
RU2724738C2 (ru) * 2015-08-05 2020-06-25 СеллабМЕД ИНК. Химерный антигенный рецептор и т-клетки, в которых экспрессируется химерный антигенный рецептор
EP3331920A4 (en) 2015-08-07 2019-04-03 Seattle Children's Hospital, dba Seattle Children's Research Institute T CARRIER CARRIER CELLS FOR BISPECIFICATION OF SOLID TUMOR TARGETING
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
EP3344996A2 (en) 2015-09-03 2018-07-11 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
EP3355937A4 (en) 2015-09-28 2019-04-17 Regents of the University of Minnesota CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
CA3001008A1 (en) 2015-10-05 2017-04-13 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
CN117070468A (zh) * 2015-10-05 2023-11-17 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
PT3362470T (pt) * 2015-10-13 2021-12-10 Hope City Recetores de antigénios quiméricos que contêm um domínio de clorotoxina
JP2018537970A (ja) * 2015-11-05 2018-12-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 養子ｔ細胞療法のための細胞を調製する方法
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
MA43380A (fr) 2015-12-03 2018-10-10 Juno Therapeutics Inc Récepteurs chimériques modifiés et compositions et procédés associés
EP4212166A1 (en) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Compositions and methods for reducing immune responses against cell therapies
UA126373C2 (uk) 2015-12-04 2022-09-28 Новартіс Аг Композиція і спосіб для імуноонкології
MA43377A (fr) 2015-12-04 2021-05-19 Hutchinson Fred Cancer Res Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
RU2757308C2 (ru) * 2016-02-05 2021-10-13 Сити Оф Хоуп Введение сконструированных т-клеток для лечения рака центральной нервной системы
MA43759A (fr) 2016-03-16 2018-11-28 Jason Connor Procédés de conception adaptative d'un régime de traitement et traitements associés
WO2017161208A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
CN108884144B (zh) 2016-03-18 2023-03-14 弗雷德哈钦森癌症中心 用于cd20免疫疗法的组合物和方法
MA44486A (fr) 2016-03-22 2019-01-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
ES2937699T3 (es) 2016-04-22 2023-03-30 Crage Medical Co Ltd Composiciones y métodos de inmunoterapia celular
EP3455261B1 (en) 2016-05-13 2022-08-03 BioAtla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109562127A (zh) 2016-06-03 2019-04-02 纪念斯隆-凯特琳癌症中心 作为早期治疗选择的过继细胞疗法
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
EP3468599A2 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
EP3469000A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP6751165B2 (ja) 2016-06-08 2020-09-02 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
WO2017214462A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
JP6987134B2 (ja) 2016-06-27 2021-12-22 ジュノー セラピューティクス インコーポレイテッド ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
CA3031734A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
BR112019005633A8 (pt) 2016-09-23 2023-04-11 Hutchinson Fred Cancer Res Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos
CA3038897A1 (en) 2016-09-28 2018-04-05 Atossa Genetics Inc. Methods of adoptive cell therapy
JP7217970B2 (ja) 2016-10-07 2023-02-06 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
MA50839A (fr) 2016-10-13 2019-08-21 Juno Therapeutics Inc Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
JP7100028B2 (ja) 2016-10-20 2022-07-12 セルジーン コーポレイション セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
CN110139669A (zh) 2016-11-03 2019-08-16 朱诺治疗学股份有限公司 T细胞疗法和btk抑制剂的组合疗法
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
CA3042424A1 (en) 2016-11-04 2018-05-11 Bluebird Bio, Inc. Anti-bcma car t cell compositions
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2019006090A (es) 2016-11-23 2019-08-21 Novartis Ag Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos.
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
EP3548048A4 (en) * 2016-12-02 2020-07-01 Cartesian Therapeutics, Inc. CANCER IMMUNOTHERAPY WITH CD8 + HIGHLY ENRICHED CHIMERIC ANTIGEN RECEPTOR T CELLS
ES2961666T3 (es) 2016-12-03 2024-03-13 Juno Therapeutics Inc Métodos para determinar la dosificación de células CAR-T
US20190358262A1 (en) 2016-12-03 2019-11-28 Juno Therapeutics, Inc. Methods for modulation of car-t cells
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
AU2017371329A1 (en) * 2016-12-09 2019-06-06 The Uab Research Foundation Chimeric chlorotoxin receptors
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
WO2018132518A1 (en) 2017-01-10 2018-07-19 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
AU2018222749B2 (en) 2017-02-17 2024-04-18 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
US20200191774A1 (en) 2017-02-27 2020-06-18 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
CA3056393A1 (en) 2017-03-14 2018-09-20 Juno Therapeutics, Inc. Methods for cryogenic storage
KR102375033B1 (ko) 2017-03-15 2022-03-15 프레드 헛친슨 켄서 리서치 센터 고친화도 mage-a1-특이적 tcr 및 이의 용도
AU2018237159A1 (en) 2017-03-22 2019-09-05 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
WO2018191723A1 (en) 2017-04-14 2018-10-18 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CA3061945A1 (en) 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
AU2018271991B2 (en) 2017-05-24 2024-07-11 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019002633A1 (en) 2017-06-30 2019-01-03 Cellectis CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
JP2020529834A (ja) 2017-06-30 2020-10-15 プレシジョン バイオサイエンシズ，インク． Ｔ細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変ｔ細胞
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
US20210106618A1 (en) 2017-09-06 2021-04-15 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
EP3678689A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Strep-tag specific binding proteins and uses thereof
JP7407701B2 (ja) 2017-09-06 2024-01-04 フレッド ハッチンソン キャンサー センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
US20200352996A1 (en) * 2017-09-27 2020-11-12 Ohio State Innovation Foundation Tissue factor-targeting car-nk and car-t cell therapy
TW202428622A (zh) 2017-10-18 2024-07-16 瑞士商諾華公司 用於選擇性蛋白質降解的組合物及方法
US20210069241A1 (en) 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
BR112020008565A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc processo para a produção de uma composição de célula t
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
CN118530373A (zh) * 2017-11-10 2024-08-23 朱拉生物公司 基于主要组织相容性复合物的嵌合受体和其用于治疗自身免疫性疾病的用途
JP2019088674A (ja) * 2017-11-16 2019-06-13 株式会社大一商会 遊技機
JP2019088676A (ja) * 2017-11-16 2019-06-13 株式会社大一商会 遊技機
EP3713584A1 (en) * 2017-11-20 2020-09-30 Prospect Chartercare RWMC LLC D/B/A Roger Williams Medical Center Compositions for improving car-t cell functionality and use thereof
CN111989106A (zh) 2017-12-01 2020-11-24 朱诺治疗学股份有限公司 基因工程化细胞的给药和调节方法
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
EA202091407A1 (ru) 2017-12-08 2020-10-20 Джуно Терапьютикс, Инк. Состав бессывороточной среды для культивирования клеток и способы его применения
BR112020011215A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc processo para a produção de uma composição de células t modificadas
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CN111971053A (zh) * 2018-02-12 2020-11-20 综合医院公司 靶向肿瘤微环境的嵌合抗原受体
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US20210046159A1 (en) 2018-03-09 2021-02-18 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
MX2020009464A (es) * 2018-03-14 2021-01-15 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Inmunoterapia de células t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13.
IL277883B2 (en) 2018-04-12 2023-12-01 Prec Biosciences Inc Optimized engineered nucleases with specificity for the human T cell receptor alpha constant region gene
US20210223248A1 (en) 2018-06-01 2021-07-22 Fred Hutchinson Cancer Research Center Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
KR20210059715A (ko) 2018-08-09 2021-05-25 주노 쎄러퓨티크스 인코퍼레이티드 통합된 핵산 평가 방법
WO2020043899A1 (en) 2018-08-31 2020-03-05 Invectys Chimeric antigen receptors against multiple hla-g isoforms
WO2020068702A1 (en) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
NL2021789B1 (en) 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
MX2021005021A (es) 2018-11-06 2021-08-11 Juno Therapeutics Inc Proceso para producir celulas t geneticamente modificadas.
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
US20220008465A1 (en) 2018-11-16 2022-01-13 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
WO2020113188A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
AU2019387497A1 (en) 2018-11-30 2021-06-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
KR20210138565A (ko) * 2018-12-19 2021-11-19 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 키메라 항원 수용체를 발현하는 점막-관련 불변 t(mait) 세포
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
SG11202111130SA (en) 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
KR20220031614A (ko) 2019-06-07 2022-03-11 주노 쎄러퓨티크스 인코퍼레이티드 자동화된 t세포 배양
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
CN114945382A (zh) 2019-11-26 2022-08-26 诺华股份有限公司 Cd19和cd22嵌合抗原受体及其用途
IL293393A (en) 2019-12-06 2022-07-01 Juno Therapeutics Inc Cell therapy-related toxicity and response-related methods for the treatment of b-cell malignancies
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
WO2021113776A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
IL294715A (en) 2020-01-23 2022-09-01 Childrens Medical Ct Corp Inducible t-cell differentiation from human pluripotent stem cells
WO2021154543A2 (en) * 2020-01-31 2021-08-05 City Of Hope TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Rα2 POSITIVE MALIGNANCIES
EP4110823A1 (en) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
CA3175123A1 (en) * 2020-03-12 2021-09-16 City Of Hope Targeted chimeric antigen receptor modified t cells for treatment of il13r.alpha.2 positive malignancies
EP4142723A2 (en) 2020-04-28 2023-03-08 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
CN115835873A (zh) 2020-05-13 2023-03-21 朱诺治疗学股份有限公司 用于产生表达重组受体的供体分批细胞的方法
WO2021231657A1 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
KR20230095918A (ko) 2020-08-05 2023-06-29 주노 쎄러퓨티크스 인코퍼레이티드 Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
CN116724053A (zh) 2020-09-24 2023-09-08 弗雷德哈钦森癌症中心 靶向sox2抗原的免疫治疗
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
NL2026614B1 (en) 2020-10-02 2022-06-03 Academisch Ziekenhuis Leiden T cell receptors directed against bob1 and uses thereof
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
WO2022125387A1 (en) * 2020-12-08 2022-06-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
KR20220082775A (ko) 2020-12-10 2022-06-17 주식회사 유틸렉스 항-pd-1 항체 및 이의 용도
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2022149837A1 (ko) 2021-01-05 2022-07-14 (주)에임드바이오 항-fgfr3 항체 및 이의 용도
US20220241328A1 (en) 2021-01-11 2022-08-04 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20240108654A1 (en) 2021-03-03 2024-04-04 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
CA3212343A1 (en) 2021-03-17 2022-09-22 Kazunori YOSHIKIYO Gene encoding a chimeric receptor for an anti-acetylcholine receptor autoantibody
EP4314814A1 (en) 2021-03-22 2024-02-07 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
US20240181052A1 (en) 2021-03-29 2024-06-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
WO2022221737A1 (en) 2021-04-16 2022-10-20 Juno Therapeutics, Inc. T cell therapy in patients who have had prior stem cell transplant
CN118201618A (zh) 2021-04-16 2024-06-14 细胞基因公司 与bcma定向t细胞疗法的组合疗法
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
TW202317602A (zh) 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
WO2023000036A1 (en) * 2021-07-22 2023-01-26 The Westmead Institute for Medical Research Chimeric antigen receptor useful in treating cancer
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
IL310862A (en) 2021-08-16 2024-04-01 Hemogenyx Pharmaceuticals Llc Antibodies against FLT3, chimeric antigen receptors, chimeric antigen receptor T cells and methods of use
EP4426339A1 (en) 2021-11-03 2024-09-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4176895A1 (en) * 2021-11-08 2023-05-10 AvenCell Europe GmbH Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
TW202342757A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科附著醣蛋白
TW202342498A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科融合醣蛋白
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
NL2030990B1 (en) 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
WO2023156587A1 (en) 2022-02-18 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
NL2031118B1 (en) 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023237663A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
NL2032130B1 (en) 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024047110A1 (en) 2022-08-31 2024-03-07 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
NL2033510B1 (en) 2022-11-11 2024-05-28 Academisch Ziekenhuis Leiden T cell receptors directed against cancer-associated antigens and uses thereof
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024141977A1 (en) 2022-12-29 2024-07-04 Astellas Pharma Inc. Engineered natural killer cells and related methods
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024219973A1 (en) 2023-04-21 2024-10-24 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Rcn1-derived teipp neoantigens and uses thereof
WO2024219974A1 (en) 2023-04-21 2024-10-24 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Timp3-derived teipp neoantigens and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2074825C (en) 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
PT1100529E (pt) 1998-07-30 2005-10-31 Us Gov Health & Human Serv A timosina beta 4 promove a preparacao de feridas
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) * 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030171546A1 (en) 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US6979359B2 (en) * 2003-07-16 2005-12-27 Laiti Peter J Portable filter unit and methods for using same
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
PT2126054T (pt) * 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias

Also Published As

Publication number Publication date
EP2331566B1 (en) 2015-10-07
PL3006459T3 (pl) 2022-01-17
JP2017221211A (ja) 2017-12-21
HUE058891T2 (hu) 2022-09-28
HRP20211788T1 (hr) 2022-02-18
EP2331566A1 (en) 2011-06-15
EP2331566A4 (en) 2012-07-18
CA2735456A1 (en) 2010-03-04
EP4032552A1 (en) 2022-07-27
ES2899174T3 (es) 2022-03-10
US8822647B2 (en) 2014-09-02
JP2012501180A (ja) 2012-01-19
WO2010025177A1 (en) 2010-03-04
EP3006459B1 (en) 2021-10-06
US20120148552A1 (en) 2012-06-14
CA2735456C (en) 2021-11-16
EP4032552B1 (en) 2023-10-04
ES2553421T3 (es) 2015-12-09
SI3006459T1 (sl) 2022-01-31
DK3006459T3 (da) 2021-12-06
ES2961498T3 (es) 2024-03-12
CA3138111A1 (en) 2010-03-04
EP3006459A1 (en) 2016-04-13
PT3006459T (pt) 2021-11-26

Similar Documents

Publication Publication Date Title
HK1223944A1 (zh) 強化 細胞抗腫瘤效應物運作的方法及複合物
HK1153233A1 (zh) 用於產生 -和 -缺陷細胞系的方法和組合物
IL202329A0 (en) Methods and compositions for stimulating cells
HK1153360A1 (zh) 增甜劑組合物及其製備方法
EP2475632A4 (en) Monochlorotrifluoropropene compounds and compositions and methods using same
EP2334185A4 (en) COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
IL213938A0 (en) Compositions and methods for assessing cytotoxicity of single cells
IL217389A0 (en) Methods and compositions for the recombinant biosynthesis of n-alkanes
PL2213648T3 (pl) Formulacje aldehydo-aminowe oraz sposób ich wytwarzania i stosowania
ZA200809978B (en) Method for selection of transformed cells
HK1151438A1 (zh) 氣體瀉流組合物以及製造和使用其的方法
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
GB0703525D0 (en) Method of making sweetner compositions
PL2328402T3 (pl) Sposoby i kompozycje do wydłużenia okresu przechowywania owoców
HK1182311A1 (en) Nutritive compositions and methods of using same
EP2357472A4 (en) METHOD FOR ASSESSING THE STATE OF CELLS
GB0913976D0 (en) Method of performing market research
EP2206402A4 (en) MULTICAST METHOD
TWI340474B (en) Method of forming semiconductor structure
GB0802079D0 (en) Method and compositions
AU2008900505A0 (en) Methods and compositions for inhibiting growth of cancerous cells
GB0702107D0 (en) Method and Uses of Compunds
GB0819376D0 (en) Method for culturing human plasma cells